GlassScriptPhysician profile
Cheryl Lynn Townsend
NPI 1548315914
$4,123.94
in general payments reported to CMS, 2019-2025
35 companies · $382 in 2025
The $382 reported for 2025 was more than what 80% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $838 · 2023: $1,056 · 2024: $1,663 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,401.07 | 2021-2025 | |
| Lilly USA, LLC | $359.11 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $225.09 | 2023-2024 | Ingrezza, Ongentys |
| Novo Nordisk INC | $215.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $192.14 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.90 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.79 | 2022-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $124.82 | 2023-2024 | Gemtesa |
| Pfizer INC. | $102.44 | 2023-2024 | |
| Lundbeck LLC | $97.05 | 2023-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $94.05 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $86.81 | 2022-2023 | Uzedy, Austedo Xr, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.42 | 2023-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $84.11 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.47 | 2022-2025 | Farxiga, Breztri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $74.02 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $65.62 | 2023-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $50.86 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $50.19 | 2023-2025 | Rexulti |
| Dexcom, INC. | $48.94 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $46.48 | 2024-2025 | Veozah |
| Gilead Sciences, INC. | $43.18 | 2024 | |
| Novartis Pharmaceuticals Corporation | $39.67 | 2024 | |
| Phathom Pharmaceuticals, INC. | $31.42 | 2024 | Voquezna |
| Ardelyx, INC. | $30.98 | 2024 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $29.05 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $27.11 | 2022-2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Seqirus USA INC | $20.74 | 2023 | Flucelvax Quadrivalent |
| Mylan Specialty L.P. | $17.89 | 2023 | Yupelri |
| Exact Sciences Corporation | $17.28 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $15.83 | 2025 | Inceptiv |
| Exeltis, USA INC. | $13.64 | 2024 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $13.31 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.75 | 2022 | |
| Organon LLC | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.